Geldanamycin (30562-34-6) inhibits HSP90 by binding to its ATP-binding domain (Kd=1.2 μM) and subsequently inhibits HSP90 client proteins. Geldanamycin induces apoptosis in various cell types. Cell permeable.
1) Neckers et al. (1999), Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity; Invest. New Drugs, 17 361
2) Zang et al. (2006), HSP90 protects apoptotic cleavage of vimentin in geldanamycin-induced apoptosis; Mol. Cell. Biochem., 281 111